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a  b  s  t  r  a  c  t
Vaccination  with  HIV/SIV  DNAs  elicits  potent  T-cell  responses.  To  improve  humoral  immune  responses,
we  combined  DNA  and  protein  in a co-immunization  protocol  using  in  vivo  electroporation  in mice
and  macaques.  DNA&protein  co-immunization  induced  higher  antibody  responses  than  DNA  or  protein
alone,  or  DNA prime/protein  boost  in mice.  DNA&protein  co-immunization  induced  similar  levels  of
cellular  responses  as  those  obtained  by  DNA  only  vaccination.  The  inclusion  of SIV or HIV Env gp120
protein  did  not  impair  the  development  of  cellular  immune  responses  elicited  by  DNA  present  in  the
vaccine  regimen.  In  macaques,  the  DNA&protein  co-immunization  regimen  also  elicited higher  levels
of  humoral  responses  with  broader  cross-neutralizing  activity.  Despite  the  improved  immunogenicity
of  DNA&protein  co-immunization,  the  protein  formulation  with  the  EM-005  (GLA-SE)  adjuvant  furtherntibody
eutralizing antibody
djuvant
ellular responses
umoral responses
endritic cell maturation
increased  the anti-Env  humoral  responses.  Dissecting  the contribution  of  EM-005,  we  found  that  its
administration  upregulated  the  expression  of  co-stimulatory  molecules  and stimulated  cytokine  pro-
duction,  especially  IL-6,  by  dendritic  cells  in vivo.  These  terminally  differentiated,  mature,  dendritic  cells
possibly  promote  higher  levels  of  humoral  responses,  supporting  the  inclusion  of  the  EM-005  adjuvant
with  the  vaccine.  Thus,  DNA&protein  co-immunization  is  a promising  strategy  to improve  the  rapidity
of  development,  magnitude  and  potency  of the  humoral  immune  responses.
e Aut© 2013 Th
. Introduction
Numerous HIV vaccine modalities have been tested in different
nimal models and 3 phase III efﬁcacy trials have been completed.
 combination vaccine consisting of recombinant Canarypox
LVAC®-HIV together with gp120 Env protein (AIDSVAX® B/E)
sed in RV144 clinical trial in Thailand [1] resulted in modest
rotection from HIV-1 infection, which correlated with anti-Env
inding antibodies (bAb), especially IgG antibodies against the
1V2 region [2,3]. No evidence of vaccine-induced virus con-
rol was found in the individuals who became infected. Using
he macaque model and repeated low dose SIV virus challenge,
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different vaccine regimens showed delay virus acquisition [4–9]
and reduction of viremia [4,5,7,8]. Although correlates of immune
protection against HIV infection are still unclear, an efﬁcient vac-
cine should elicit both cellular and humoral responses. We  and
others have previously shown that vaccination of macaques with
optimized SIV/HIV DNAs induces strong, long-lasting humoral and
cellular immune responses [8,10–16], which are able to control
SIV/SHIV viremia [11,12,14–16]. Although DNA vaccines induce
robust immunity, responses have not provided sterilizing protec-
tion. To enhance immunogenicity, other vaccine strategies used a
prime/boost regimen with plasmid DNA followed by viral vector
or protein boost [reviewed in Refs. [17–19]]. DNA priming and Env
protein boost provided protection from homologous challenge in
macaque SHIV models [20,21] and was immunogenic in humans
[22,23]. In the present work, we evaluated the immunogenicity of a
HIV/SIV vaccine consisting of DNA or protein only immunization or
of DNA and gp120 Env protein as a boost or upon co-immunization.
Open access under CC BY-NC-ND license. We also tested the contribution of EM-005 (GLA-SE) [24] as adju-
vant and showed that its inclusion further increased the humoral
responses obtained with the DNA&protein co-immunization regi-
men  in macaques.
NC-ND license. 
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Fig. 1. DNA&protein co-immunization induces highest Env bAb in vaccinated mice. (A) Mice (N = 5) were immunized twice (week 0 and 4) with DNA only; protein only;
co-immunized with DNA&protein; or received a DNA prime/protein boost (DNA/protein). Blood was  collected 2 weeks after the 1st and the 2nd vaccinations (V) and the
mice  were sacriﬁced at week 6. (B) Humoral immune responses of mice that received SIV gag and HIV gp160 env DNA and/or HIV gp120 protein. Env-speciﬁc (upper panel)
and  SIV Gag-speciﬁc (bottom panel) bAb were measured at 2 weeks after 2nd vaccination. Endpoint antibody titers of individual mice (mean ± SEM) from a representative
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iters  from individual mice from a representative out of 2 independent experiment
. Materials and methods
.1. Vaccine
Expression-optimized [25,26] endotoxin-free DNA vectors for
IV Gag and Env, HIV-1 Env and IL-12 and the gp120 proteins
IVBaL and SIVmac251 (transmitted clone M766) are described (see
upplementary Methods).
.2. Vaccination of mice
BALB/c mice were vaccinated with 10 g of DNA mixture con-
aining Env and Gag plasmids in 50 l PBS injected IM followed
y in vivo electroporation (EP) (Ichor Medical Systems, Inc., San
iego, CA). Two  g of gp120 Env proteins were formulated with
 g EM-005, an oil-in-water emulsion containing a TLR-4 agonist,
s adjuvant in a 50 l volume [24] and injected by conventional IM
njection following the DNA electroporation, at the same sites as
NA.
.3. Vaccination of rhesus macaques
Macaques were immunized by IM injection with 1 mg  plas-
id  DNA followed by EP (ICHOR Medical Systems, Inc.) with a
NA vaccine mixture consisting of SIV Gag DNA, HIV Env DNA
nd IL-12 DNA formulated in 1 ml  PBS. The HIV-1 gp120 protein
as formulated in 100 l PBS alone or adjuvanted with 20 g ofann–Whitney). (C) Humoral immune responses of mice that received SIV gag and
c (bottom panel) bAb were measured as described for panel B. Endpoint antibody
hown. Mean ± SEM and P values are indicated (t test).
EM-005 and delivered by conventional IM injection at the same
sites as DNA.
2.4. Immunological assays
Cellular responses in splenocytes and the phenotype and
cytokine production of dendritic cells (DCs) were monitored using
ﬂow cytometry, and humoral immune responses were monitored
for bAb and neutralizing (NAb) antibodies (see Supplementary
Methods).
3. Results
3.1. DNA&protein co-immunization elicits high levels of humoral
immune responses in mice
Different vaccination strategies with DNA and protein, either
alone or in combination using a standard prime/boost or a co-
immunization regimen, were compared in mice (N = 5 per group)
after two immunizations (Fig. 1A). The DNA component of the
vaccine was  a mixture of plasmids encoding SIV Gag and SIV or
HIV-1 Env, whereas the protein component consisted of SIV or HIV
gp120 Env adjuvanted in EM-005 (GLA-SE). Blood was collected and
assessed for the presence of Env and Gag bAb responses. DNA only,
gp120/EM-005 only, or the DNA prime/protein boost immuniza-
tion regimens yielded similar Env bAb titers (Fig. 1B, upper panel).
In contrast, the DNA&protein/EM-005 co-immunization regimen
J. Li et al. / Vaccine 31 (2
Fig. 2. DNA&protein co-immunization of macaques. (A) Macaques (N = 3) were
immunized twice (week 0 and 4) and 2 weeks after the 2nd vaccination, plasma
was  collected for endpoint bAb titer determination. The animals were vaccinated
with DNA only or with the DNA&protein co-immunization regimen using gp120
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plone or adjuvanted in EM-005. (B) Endpoint titers of Env-speciﬁc (upper panel) and
ag-speciﬁc (lower panel) bAb are shown. The p values from the one-way ANOVA
nalysis with Bonferroni’s multiple comparisons test are given.
licited signiﬁcantly higher (5–10 fold) responses. A vaccine that
ontained SIV gp160 Env DNA and gp120 protein/EM-005 instead
f the HIV components also showed that the co-immunization
egimen induced signiﬁcantly higher bAb titers than any of the
ther vaccine regimens (Fig. 1C, upper panel). Both studies fur-
her showed that the DNA&protein co-immunization elicited
arly higher humoral responses, with differences detectable even
wo weeks after the 1st immunization (data not shown). Thus,
NA&protein co-immunization regimen is more effective in rapidly
nducing high levels of humoral immune responses.
We  also measured humoral responses to Gag, which was a com-
onent of all the DNA vaccine mixtures, but was not given as protein
Fig. 1B and C, bottom panels). Similar levels of Gag bAb were
etected 2 weeks after the 1st vaccination in all the groups that
eceived the DNA vaccine (data not shown). At 2 weeks after the
nd vaccination, the DNA-only and DNA&protein co-immunization
roups showed similar anti-Gag bAb responses, indicating that the
resence of the EM-005 adjuvanted Env protein did not impair the
evelopment of humoral immune responses to Gag. As expected,
he DNA prime/protein boost group showed lower Gag bAb lev-
ls since these animals did not receive a 2nd DNA vaccination.
ogether, the DNA&protein co-immunization (HIV and SIV vaccine
latforms) was the most efﬁcient regimen, inducing the highest
nv bAb titers without impairing the Gag bAb responses.
.2. DNA and protein co-immunization elicits higher level of
umoral immune responses in macaques
Encouraged by the mouse data, we tested the co-immunization
egimen in rhesus macaques and compared the humoral responses
fter 2 vaccinations using the same mixture of DNAs expressing
IV Gag and HIV Env, either alone or combined with HIV gp120 Env
rotein (Fig. 2A). Animals (N = 3/group) were immunized with DNA013) 3747– 3755 3749
only or DNA&protein using 100 g gp120 protein in the absence of
adjuvant. Co-immunization with HIV gp120 protein induced sig-
niﬁcantly higher bAb responses compared to the DNA only (Fig. 2B,
upper panel), while similar levels of Gag-speciﬁc bAb titers were
found in both groups (bottom panel), indicating that the presence
of Env protein in the vaccine did not affect the induction of Gag-
speciﬁc responses. These ﬁndings support the data from the mouse
studies and show that the co-immunization protocol elicits robust
humoral immune responses to Gag and Env. No impairment in the
development of either of the responses was  noted.
We further examined whether the inclusion of the EM-
005 adjuvant was able to further increase the robust humoral
responses obtained using the DNA&protein co-immunization pro-
tocol (Fig. 2B, upper panel). We tested the contribution of the
EM-005 adjuvant using 2 doses of BaL gp120 protein (100 g and
20 g). Immunization with the 100 g-dose of adjuvanted protein
showed a signiﬁcant increase (∼5×) in bAb titers, whereas interme-
diate levels of bAb titers were noted using the lower Env dose. The
presence of Env protein in the vaccine in the absence or presence of
the EM-005 adjuvant did not affect the development of Gag speciﬁc
bAb responses (Fig. 2B, bottom panel). Analysis of the neutraliza-
tion capacity of the antibodies showed that DNA&protein regimen,
especially the group that received the higher dose of adjuvanted
gp120 protein, developed NAb to several clade B Env proteins and
showed broader cross-neutralizing activity to clade A and clade
C Env (Table 1). No NAb to tier 2 Envs were induced after two
vaccinations.
In conclusion, the macaque and mouse studies show consis-
tent results and demonstrate signiﬁcantly higher Env humoral
responses upon DNA&protein co-immunization. The macaque
study further showed a positive effect of EM-005 in combination
with the efﬁcient DNA delivery by EP, indicating the importance
of inclusion of an appropriate adjuvant to maximize the humoral
immune responses in non-human primates.
3.3. DNA and protein co-immunization generates polyfunctional
cellular immune responses in mice
We next investigated the development of cellular immune
responses in mice that received the different regimens described
in Fig. 1A. The frequency of antigen-speciﬁc cellular responses was
determined in splenocytes stimulated with peptide pools covering
HIV-1 Env (Fig. 3) and SIV gag, respectively (Fig. 4), and cytokine
production was monitored by ICS staining followed by ﬂow cytom-
etry.
Mice vaccinated with DNA-only or co-immunized with
DNA&protein developed similar levels of Env-speciﬁc IFN-+ T cell
responses (Fig. 3A, B), indicating that the presence of the EM-
005 adjuvanted protein in the co-immunization regimen did not
impair the development of cellular immune responses. As expected,
immunization with the DNA prime/protein boost regimen showed
lower cellular immune responses, since a single DNA immuniza-
tion was  given. Immunization with protein only induced the lowest
levels of cellular immunity. The antigen-speciﬁc responses were
mainly mediated by CD4+ T cells. The DNA only and DNA&protein
co-immunization groups, which received 2 DNA vaccinations, had
increased levels of Env-speciﬁc CD8+ T cell responses (Fig. 3B). As
expected, splenocytes from mice immunized with sham DNA did
not respond to peptide stimulation (Fig. 3A and B, left panel).
We examined the poly-functional proﬁle of the Env-speciﬁc T
cells (Fig. 3C) by measuring their cytokine production (IFN- and
TNF-) and degranulation potential (CD107a) by ﬂow cytometry.
Mice that received two vaccinations (DNA only and DNA&protein
co-immunization) showed similar pattern of responses includ-
ing single, 2-function and 3-function within both the CD4+ and
CD8+ T cell populations. The co-immunization group had a higher
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Fig. 3. DNA and protein co-immunization elicited Env-speciﬁc polyfunctional cellular responses in mice. Splenocytes were isolated from immunized mice (described
in  Fig. 1A) at V2wk2. Sham DNA immunized mice served as negative control. The HIV Env-speciﬁc IFN- positive T cells were analyzed by ﬂow cytometry. (A). The
antigen-speciﬁc T cells (upper panel) and the distribution of IFN- positive cells in CD4+ and CD8+ T cells (bottom panel) are shown for a representative animal from each
vaccination group. (B) The mean ± SEM of Env-speciﬁc IFN-+ T cells (left panel) and the distribution in CD4+ and CD8+ T cells (right panel) for each group of mice is shown, from
J. Li et al. / Vaccine 31 (2013) 3747– 3755 3751
Table 1
DNA&protein co-immunization with EM-005 adjuvanted gp120 induces broader NAb.
Group Vaccine Animal Clade B Clade C Clade A Negative control
SF162.LS BaL.26 SS1196.1 Bx08.16 MW965.26 DJ263.8 MuLV
1 DNA A6X018 <20 <20 <20 23 22 <20 28
A5X026 <20 <20 <20 <20 24 <20 <20
A5X007 <20 <20 <20 <20 29 <20 <20
2 DNA&BaLgp120
(100 g)
A6X013 31 <20 22 20 61 <20 <20
A4X018 <20 <20 <20 <20 36 <20 <20
A4X010 64 <20 35 48 160 26 30
3 DNA&BaLgp120
(100  g) in EM-005
A4E056 398 98 83 147 498 49 35
A4E055 65 26 29 43 88 30 <20
A4X017 95 34 30 48 146 20 25
4 DNA&BaLgp120
(20  g) in EM-005
A6X006 36 34 41 56 146 40 24
A5X012 248 46 49 65 257 24 <20
A4X049 26 21 <20 20 52 <20 <20
Fig. 4. Gag-speciﬁc cellular responses induced by DNA alone and DNA&protein co-immunization in mice. Splenocytes (described in Fig. 3) were stimulated with SIV gag
peptide  pool. (A) The mean ± SEM of gag-speciﬁc IFN-+ T cells (left panel) and the distribution in CD4+ and CD8+ T cells (right panel) for each group of mice is shown, from
one  of three representative experiments. (B) Mean frequency (±SEM) of Gag-speciﬁc cells with 1 function (IFN-+, TNF-+), 2 functions (IFN-+TNF-+, IFN-+CD107a+,
TNF-+CD107a+) or 3 functions (IFN-+TNF-+CD107a+) in CD4+ T cells is shown. (C) Pie charts show the distribution of Gag-speciﬁc cells with 1 (blue), 2 (red) or 3 (green)
f
o
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runctions among the CD4+ T cells. (For interpretation of the references to color in this ﬁgu
ne of three representative experiments. (C) Mean frequency (±SEM) of Env-speciﬁc cel
NF-+CD107a+) or 3 functions (IFN-+TNF-+CD107a+) among the CD4+ and CD8+ T cell
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requency of CD4+ T cells with 3 functions than the other groups and
his difference was statistically signiﬁcant compared to the DNA
rime/protein boost group (with a single DNA dose) which elicited
ower T cell responses with reduced multi-functionality. The distri-
ution of Env-speciﬁc multifunctional T cells for all the groups that
eceived DNA as a vaccine component is shown in the pie charts
Fig. 3D). The distribution of IFN-, TNF- and multi-functionality
mong CD8+ T cells was similar both in the DNA only and the co-
mmunization group. Similar results were obtained in studies using
IV Env DNA combined with SIV gp120 protein (data not shown).
hese results show that co-immunization with DNA and protein
id not impair the induction of multifunctional cellular immune
esponses.
.4. Gag-speciﬁc cellular responses are not impaired in DNA and
rotein co-immunization protocol in mice
We  also determined whether the co-immunization protocol
ffected the development of cellular immune responses to Gag, a
econd antigen that was part of the DNA vaccine mixture but that
as not provided as protein. The level of Gag-speciﬁc IFN-+ T cells
as similar among the groups that received 2 DNA immunizations
Fig. 4A), and showed that co-administration of the adjuvanted
nv protein did not affect the development of Gag-speciﬁc cellular
esponses, excluding the possibility of a general T cell activation
nduced by the adjuvant included in the vaccine. This conclusion is
urther supported by the fact that the protein-only group did not
how any response upon stimulation with Gag peptides (Fig. 4A).
s expected, the levels of Gag-speciﬁc responses were lower in
he DNA prime/protein boost group, which only received a sin-
le DNA vaccine at prime. The Gag-speciﬁc IFN-+ T cells showed
ainly a CD4+ phenotype in all three groups. Analysis of the multi-
unctionality of the Gag-responses demonstrated similar frequency
mong the groups that received the DNA twice, including cells with
 or 3 functions. The mice from the DNA prime/protein boost had
ower degranulation potential (Fig. 4B). The pie charts show that the
istribution of 1, 2 and 3 functions between the antigen-speciﬁc T
ells is similar among the groups (Fig. 4C). These results demon-
trate that co-immunization with DNA (Gag and Env) and protein
Env) did not affect cellular responses induced by an antigen (Gag)
ncluded only as DNA.
.5. EM-005 adjuvant enhances the maturation of dendritic cells
n mice
We  further dissected the mechanism by which EM-005 con-
ributed to the increase in humoral immunity. We  hypothesized
hat the EM-005 may  stimulate the maturation of dendritic cells
DCs), thereby enhancing their functional capabilities for antigen
resentation. To explore possible effects of EM-005 on the function
f DCs, mice were immunized with HIV-1 Env DNA, gp120 protein
r DNA&protein in the presence or absence of EM-005 as adjuvant
Fig. 5A). Two days later, spleens and draining lymph nodes were
ollected and the phenotype and cytokine production of DCs was
nalyzed by ﬂow cytometry. Vaccine regimens that did not contain
he adjuvant (Fig. 5A) showed a DC phenotype similar to that of
ntreated mice (data not shown). In contrast, vaccine regimens that
ncluded the EM-005 adjuvant (EM-005 only, protein formulated
n EM-005 or DNA&protein/EM-005) resulted in DCs with a more
ature phenotype, characterized by increased expression of the
o-stimulatory molecules CD40, CD80 and CD86. As representative
xamples, we show (Fig. 5B, upper panel) the expression proﬁles
f the co-stimulatory molecules in DCs obtained from mice that
eceived protein only (gray area), DNA&protein (dashed line), EM-
05 only (gray line) and DNA&protein/EM005 (bold black line). The
ercent of CD40+, CD80+ and CD86+ cells in MHC  II+ DCs from mice013) 3747– 3755
immunized with EM-005 only or DNA&protein/EM-005 was  sig-
niﬁcantly higher than that of mice immunized with protein only
or DNA&protein (Fig. 5B, lower panel). In addition, we  found that
DCs obtained from mice injected with EM-005 produced signiﬁ-
cantly higher level of IL-6 in lymph nodes (Fig. 5C, left panel) and
spleens (Fig. 5C, right panel). Therefore, these data suggest that
EM-005 increased the immunogenicity of the adjuvanted protein
by enhancing the maturation and cytokine production of DCs.
4. Discussion
The goal of this study was  to identify an HIV vaccine platform
effective in eliciting robust and balanced immunity combining both
cellular and antibody responses. We  compared vaccination proto-
cols that used DNA, protein, or a combination of DNA and protein
delivered either in co-immunization regimen or using a classical
prime/boost regimen as outlined. The rationale for this strategy is
that DNA vaccination elicits strong cellular immunity, whereas the
induced antibody responses are lower than those obtained with
a protein vaccine. In contrast, protein vaccination provides strong
antibody response but less robust cellular immunity. Therefore, we
hypothesized that a combination of these vaccine components may
be better suited to trigger both arms of the immune system.
Here, we  report that the DNA&protein co-immunization induces
signiﬁcantly higher humoral immune responses than DNA alone,
and that co-immunization did not impair cellular immunity
resulting in the development of polyfunctional cellular immune
responses in mice. Similarly, we found that the co-immunization
regimen elicited higher humoral responses in macaques, including
broader HIV-1 cross-neutralizing antibodies. Interestingly, incor-
poration of the synthetic EM-005 adjuvant led to further signiﬁcant
increase of the humoral responses in vaccinated monkeys despite
the use of the very efﬁcient DNA EP delivery method. These results
support the concept of DNA&protein co-immunization as promis-
ing strategy for the development of an effective HIV-1 vaccine,
and show that inclusion of an adjuvant contributes to maximally
augment the humoral responses. Several studies have shown that
the EM-005 adjuvant enhances the humoral responses induced
by protein immunogens [27–32]. Here, we show that using one
of the most effective DNA delivery methods (in vivo electropo-
ration) together with protein co-immunization still beneﬁts from
the presence of this adjuvant. Addressing the mechanism for this
enhancement, we  found that the expression of co-stimulatory
molecules was upregulated ex vivo in DCs from mice that received
EM-005. DCs with more mature phenotype might migrate more
efﬁciently into secondary lymphoid organs and enhance antigen
presentation. Importantly, DC secretion of IL-6, which has been
associated with B cell activation and antibody production [33], was
signiﬁcantly increased by the EM-005 adjuvant. These data support
the conclusion that the DC activation observed in mice immunized
with DNA&protein/adjuvant is due to the effect of EM-005 and not
to other components of the co-immunization regimen. Increasing
the maturation/activation status of DCs, like EM-005 does, is the
most common feature of all TLR ligands [34], and the most likely
mechanism responsible for their adjuvant activity.
In our study, co-immunization not only induced the highest
Env bAb titers but also elicited strong cell-mediated responses.
These ﬁndings are in agreement with those obtained in a recent
macaque study where vaccines combining DNA with simulta-
neous or sequential administration of inactivated viral particles,
as a source of protein, showed that the co-immunization proto-
col induced the highest humoral responses [8]. Improved humoral
immunity induced by needle/syringe delivered DNA&protein co-
immunization compared to the individual components has been
reported for a non-HIV vaccine [35], but it was also noted that
J. Li et al. / Vaccine 31 (2013) 3747– 3755 3753
Fig. 5. The maturation and cytokine production of DCs by EM-005 adjuvant. (A) Mice (n = 3 or 4) were immunized with sham DNA, HIV-1BaL gp160 DNA only, HIV-1BaL gp120
protein  only, protein/EM-005, DNA&protein, DNA&protein/EM-005 and EM-005 only. Two  days after the injection, inguinal LN and spleens were isolated. (B) The maturation
of  DCs in inguinal LN was  analyzed by ﬂow cytometry. The overlays (upper panel) show the expression of the co-stimulatory molecules CD40, CD80 and CD86 in DCs identiﬁed
as  CD3− , CD11c+MHC  II+. Protein only (gray ﬁlled area), DNA&protein (dashed line), DNA&protein/EM-005 (black line) and EM-005 only (gray line) are shown as selective
examples. The lower panels show the percent of CD40+, CD80+ and CD86+ cells in MHC  II+ DCs. C) The IL-6 production of DCs in inguinal LN (left panel) and spleen (right
panel). Lymphocytes were incubated overnight in the presence of Monensin and IL-6 production was  monitored by intracellular staining and ﬂow cytometry. The CD11c+
population in CD3− cells was  considered to represent DCs. Mean frequency (±SEM) of IL-6+ DCs in inguinal LN and spleen is shown. One-way ANOVA was used to analyze
the  difference between each of the vaccines that lacked (open symbols) or included (ﬁlled symbols) EM-005. *P < 0.05.
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o-immunization resulted in active immune suppression lead-
ng to impaired cellular responses [35–38]. Subsequent works
esting some non-HIV vaccines showed that DNA&protein co-
mmunization resulted in T cell anergy secondary to induction of
nhibitory Treg responses via regulatory DCs [39,40], and, therefore,
t was proposed as a method to induce tolerance in autoim-
une and allergic diseases [41–44]. In contrast, DNA&protein
o-immunization was also reported to greatly augment humoral
esponses in other systems [45–47] with no impairment of cellular
mmunity [48]. Combining Dengue DNA vaccine with particles in
 co-immunization protocol demonstrated higher antibody titers,
hich associated with protection from Dengue viremia in immu-
ized mice [49]. In agreement with the latter, we recently reported
hat the co-delivery of electroporated DNA and inactivated viral
articles resulted in robust immune responses without any evi-
ence of tolerance, because the vaccinated macaques resisted
nfection and controlled chronic virus replication [8]. Using the
ouse model with DNA and puriﬁed Env protein as vaccine
omponents, we report superior induction of humoral immu-
ity with no negative effect on the cellular immune responses
sing the co-immunization regimen. We  hypothesize that the
ifferent DNA delivery methods, (needle/syringe [35,36] versus
M/EP (this report), the amounts of DNA and protein used or
he nature of immunogens could contribute to the discrepancies
n these ﬁndings. In our DNA&protein co-immunization protocol
sing electroporation, we did not observe induction of Treg cells
data not shown) or impairment of cellular responses compared
o DNA only group. While our studies were on-going, Jaworski
t al. [50] reported that HIV DNA&protein co-immunization was
uperior to vaccination with either of the two individual com-
onents in eliciting humoral immune responses in rabbits and
ice. Our results are in overall agreement and we further expand
hese ﬁndings to the rhesus macaque model, which is consid-
red the most relevant for human vaccination. Jaworski et al.
50] reported that DNA&protein co-immunization also enhanced
ntigen-speciﬁc cellular immune responses compared to either
NA or protein alone in mice. In contrast, our results show that
NA&protein co-immunization induced similar levels of cellular
mmune responses compared to DNA and that these levels are
igher than those found in the protein only group. It is possible
hat the efﬁciency of the different DNA delivery methods used
n these studies (conventional intramuscular injection for DNA
elivery [50] versus in vivo electroporation) could contribute to
his.
We have previously shown that DNA&protein co-immunization
nduces robust immune responses in the absence of exogenous
djuvant [8]. Since the protein component was provided as inactiv-
ted viral particles at low concentration, we could not exclude
n adjuvant effect provided by other particle components. Here,
e show that the DNA&protein co-immunization regimen using
uriﬁed protein in the absence of adjuvant elicits higher humoral
esponses and that these responses can be further augmented using
he EM-005 adjuvant. DNA&protein co-immunization not only elic-
ts high Env bAb titers but it also induces polyfunctional cellular
mmune responses. Importantly, this strategy induces robust levels
f antibodies with cross-clade neutralizing activity in the macaque
odel. The DNA&protein co-immunization platform provides a
romising HIV-1 vaccine candidate with potentially improved efﬁ-
acy.
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